Successful Treatment of Chronic Staphylococcus aureus-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases

Abstract

Staphylococcus aureus plays an important role in skin and soft tissue infections and contributes to the pathophysiology of complex skin disorders such as atopic dermatitis. Bacterial resistance against commonly used antibiotics has increased considerably in the last decades demanding alternative treatment approaches. We present 3 cases where patients with chronic and recurrent S. aureus-related dermatoses were successfully treated with Staphefekt SA.100. Staphefekt SA.100 is a recombinant phage endolysin for topical skin application that specifically targets both methicillin-sensitive and methicillin-resistant S. aureus. As a consequence of its specific mechanism of action, bacterial resistance is unlikely to develop. In our 3 cases, resistance induction was not observed. Our results indicate that targeted treatment with Staphefekt might be an attractive alternative for (long-term) classical antibiotic therapy, and confirmatory randomized controlled trials are warranted to evaluate its clinical efficacy and safety.

Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus ?

“…Several formulations, such as creams and gels, are currently commercialized under the Gladskin brand. It has recently been demonstrated that this product can successfully treat chronic and recurrent S. aureus -related dermatoses without generating bacterial resistance after long-term daily therapy ( 60 ).…”

In Vitro Antibacterial Activity of Medicinal Plants in the Central North of Morocco: A Possible Source of Alternative Drugs Against Methicillin-Resistant Staphylococcus Aureus

“…Staphylococcus species are opportunistic bacteria and the most pathogenic species. Strains of Staphylococcus aureus are able to colonize all tissues [1], secrete various enzymes and toxins [2][3][4] and cause various diseases including skin infections [5,6]. Microbial infections are normally treated using antibiotics, but the development of resistant strains award current antibiotics has become increasingly common which constitutes a growing public health problem, especially since these multi-resistant strains are no longer confined to hospital environments but are also found in the community [7,8].…”

Phage Therapy in the Postantibiotic Era

“…Another example of current endolysin therapies is the topical use of the recombinant endolysin Staphefekt to treat skin flora dysbiosis caused by overgrowth of S. aureus. Staphefekt was able to decrease the load of S. aureus, restore the balance of the local flora, and clinically improve the condition in three patients (134) and has now progressed through to phase II clinical trials (135).…”